Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
To come full circle, that’s what GLP-1 drugs are. A medical intervention for an addiction. Same as methadone. It’s not a coincidence that GLP-1 drugs also curb cravings for other addictive behaviors.
And that’s why the snark of the “Did you know you can just eat less to lose weight?” falls flat, because it’s completely uninformed.